跳至主要内容
临床试验/NCT04282343
NCT04282343已完成不适用

A Phase 2 Trial of the Discussion of Cost (DISCO) App as an Intervention to Improve Financial Outcomes in Hematologic Cancer Patients

Barbara Ann Karmanos Cancer Institute2 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2020年2月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
25
试验地点
2
主要终点
Presence of cost discussion observed via video recordings of patient-physician treatment discussions.

研究概览

简要总结

This phase II trial studies how well the DIScussion of COst (DISCO) application (app) works in improving financial outcomes in patients with hematologic cancer. The DISCO app is an electronic, highly scalable and tailorable education and communication intervention that may help researchers learn more about improving how patients and oncologists discuss cancer treatment costs

详细描述

PRIMARY OBJECTIVE:

I. To assess the effectiveness of the DISCO app on prompting patient-oncologist treatment cost discussions during patient-physician interactions (as observed in video recordings), patient outcomes related to financial toxicity immediately after the patient-oncologist interaction, and at a 3-month follow up.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
Double (Care Provider, Outcomes Assessor)

盲法说明

Trained research assistants and oncologists

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ONCOLOGISTS: Eligible if they treat patients with chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), or multiple myeloma (MM) cancers
  • PATIENTS: Able to read and write in English
  • PATIENTS: Have a confirmed diagnosis of CLL, CML, or MM cancers
  • PATIENTS: Are scheduled to see an oncologist at Karmanos Cancer Institute (KCI) Detroit or KCI Farmington Hills/Weisberg for an initial or change in treatment discussion

排除标准

  • 未提供

结局指标

主要结局

Presence of cost discussion observed via video recordings of patient-physician treatment discussions.

时间窗: Observed during the video-recorded patient-physician interaction.

Number of participates who have a treatment cost discussion will be evaluated with a validated observational scale. This is an investigator-developed scale and its called the Discussion of Cost (DISCO) scale. A higher score means a better outcome.

次要结局

  • Referrals for financial or psychological support(Immediately after the patient-physician interaction)
  • Financial toxicity(3 months after the patient-physician interaction)
  • Self-efficacy in managing treatment cost(Immediately after the patient-physician interaction)
  • Self-efficacy in patient-physician interactions(Immediately after the patient-physician interaction)
  • Treatment cost distress(Immediately after the patient-physician interaction)
  • Anticipated material hardship(Immediately after the patient-physician interaction)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lauren Hamel

Principal Investigator

Barbara Ann Karmanos Cancer Institute

研究点 (2)

Loading locations...

相似试验

进行中(未招募)
2 期
PMT for MDRO DecolonizationMultidrug Resistant Bacterial InfectionEnterobacteriaceae InfectionsPseudomonas AeruginosaVRE InfectionMethicillin-resistant Staphylococcus Aureus
NCT05632315University of Pennsylvania32
进行中(未招募)
不适用
Comparing Virtual Yoga to Standard Care on Insomnia Among Cancer SurvivorsInsomnia
NCT04458194University of Rochester42
进行中(未招募)
1 期
A study with the aim to evaluate the antitumor activity of a new association of oral drugs, lenalidomide and clarithromycin in patients with lymphoma (MALT), when standard treatment with radiation therapy, chemotherapy and / or immunotherapy have shown a lack of efficacy.Patients with lymphoid tissue lymphoma mucosa-associated (MALT) for which the standard treatments with radiotherapy, chemotherapy and / or immunotherapy show lack of efficacy.MedDRA version: 21.0Level: PTClassification code 10015823Term: Extranodal marginal zone B-cell lymphoma (MALT type) recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10015824Term: Extranodal marginal zone B-cell lymphoma (MALT type) refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-003168-35-ITIELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP68
进行中(未招募)
1 期
A phase II trial clarithromycin + lenalidomide combination:for patients with relapsed/refractory extranodal marginal zone lymphomaextranodal marginal zone lymphoma (MALT)
EUCTR2015-003168-35-ATIELSG International Extranodale Lymphoma Study Group; Instituto Oncologico della Svizzera Italiana,68
已完成
2 期
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on OlaparibOvarian Cancer
NCT02340611University Health Network, Toronto4